胆汁淤积
肝损伤
多药耐药蛋白2
医学
内科学
分泌物
内分泌学
化学
生物化学
ATP结合盒运输机
基因
运输机
作者
Zewei Zhao,Siqi Liu,Shiya Luo,Lin Zhou,Junxi Liu,Bingxiu Qian,Jianglin Shi,Yayun Zhou,Jin Li,Tao Jiang,Ziquan Lv,Zhonghan Yang
出处
期刊:Cytokine
[Elsevier]
日期:2022-10-01
卷期号:158: 155979-155979
标识
DOI:10.1016/j.cyto.2022.155979
摘要
Cholestasis caused by bile secretion and excretion disorders is a serious manifestation of hepatopathy. Interleukin (IL)-25 is a member of the IL-17 cytokine family, which involves in mucosal immunity and type 2 immunity via its receptor-IL-17RB. Our previous studies have shown that IL-25 improves non-alcoholic fatty liver via stimulating M2 macrophage polarization and promotes development of hepatocellular carcinoma via alternative activation of macrophages. These hepatopathy are closely associated with cholestasis. However, whether IL-25 play an important role in cholestasis remains unclear. IL-25 treatment and IL-25 knockout (Il25-/-) mice were injected intragastrically with α-naphthyl isothiocyanate (ANIT) to determine the biological association between IL-25 and cholestasis. Here, we found that IL-25 and IL-17RB decreased in ANIT-induced cholestatic mice. Il25-/- mice showed exacerbated ANIT-induced parenchymal injury and IL-25 treatment significantly alleviated cholestatic liver injury induced by ANIT. We found that IL-25 reduced the level of hepatic total bile acids and increased the expression of multidrug resistance-associated protein 2 (MRP2) and multidrug resistance-associated protein 3 (MRP3) in liver. In conclusion, IL-25 exhibited a protective effect against ANIT-induced cholestatic liver injury in mice, which may be related to the regulation on bile acids secretion. These results provide a theoretical basis for the use of IL-25 in the treatment of cholestatic hepatopathy.
科研通智能强力驱动
Strongly Powered by AbleSci AI